ARTIVION, INC.(AORT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,743 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AORT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ARTIVION, INC. (AORT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AORT at 48.1/100 on a 32-signal composite quality model, placing it at rank #1,743 of 2,962 stocks — the bottom half of the AI-ranked universe. AORT scores in the top quartile across earnings quality (97.4). Areas of concern include free cash flow (23.6) and balance sheet strength (33.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ARTIVION, INC. reports quarterly revenue of $125.8M, net income of $-13.5M, free cash flow of $-12.0M. Top institutional holders of AORT by reported 13-F value include BlackRock, NOMURA ASSET MANAGEMENT INTERNATIONAL, MORGAN STANLEY, based on the most recent SEC filings. AORT trades on the NYSE exchange and files with the SEC under CIK 784199. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AORT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARTIVION, INC. directly from SEC EDGAR. ARTIVION, INC.'s 13F Pro composite quality score has ranged between 32 and 55 since 2022, currently 48.1 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$125.8M
Net Income
Q2 2026
$-13.5M
Free Cash Flow
Q2 2026
$-12.0M
ROIC
Q2 2026
-4.1%
D/E Ratio
Q2 2026
0.82
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+13.6% YoYNet Income
+173.1% YoYOperating Income
-13.2% YoYEPS (Diluted)
+165.6% YoYTotal Assets
+12.1% YoYTotal Debt
-31.6% YoYOp. Cash Flow
+79.3% YoYFree Cash Flow
-92.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $441.3M +13.6% | $388.5M +9.8% | $354.0M +12.8% | $313.8M +5.0% | $298.8M +18.0% | $253.2M |
| Net Income | $9.8M +173.1% | $-13.4M +56.5% | $-30.7M -59.9% | $-19.2M -29.4% | $-14.8M +11.1% | $-16.7M |
| Operating Income | $33.7M -13.2% | $38.9M +577.0% | $5.7M -7.4% | $6.2M -23.6% | $8.1M +232.5% | $2.4M |
| EPS (Diluted) | $0.21 +165.6% | $-0.32 +57.3% | $-0.75 -56.3% | $-0.48 -26.3% | $-0.38 +13.6% | $-0.44 |
| Total Assets | $884.8M +12.1% | $789.1M -0.4% | $792.4M +3.9% | $762.8M -3.8% | $793.1M +0.5% | $789.4M |
| Total Debt | $215.1M -31.6% | $314.5M +2.0% | $308.4M -0.4% | $309.7M -0.3% | $310.8M +6.1% | $292.9M |
| Operating Cash Flow | $39.9M +79.3% | $22.2M +18.1% | $18.8M +465.3% | $-5.2M -99.3% | $-2.6M -120.9% | $12.4M |
| Free Cash Flow | $839.0K -92.4% | $11.0M +21.8% | $9.1M +157.2% | $-15.9M -1.2% | $-15.7M -411.0% | $5.0M |
Get alerted when AORT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ARTIVION, INC. including:
Top Institutional Holders of AORT
BlackRock, Inc.
$150.0M6,674,017 shNOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$71.6M3,184,974 shMORGAN STANLEY
$57.5M2,557,961 shJuniper Investment Company, LLC
$45.4M2,019,885 shVANGUARD CAPITAL MANAGEMENT LLC
$45.0M2,004,619 shFMR LLC
$44.1M1,963,471 shSTATE STREET CORP
$41.8M1,858,051 shOphir Asset Management Pty Ltd
$40.4M1,800,008 shPERCEPTIVE ADVISORS LLC
$39.0M1,737,290 shConestoga Capital Advisors, LLC
$36.5M1,623,700 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $150.0M | 6,674,017 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $71.6M | 3,184,974 |
| MORGAN STANLEY | $57.5M | 2,557,961 |
| Juniper Investment Company, LLC | $45.4M | 2,019,885 |
| VANGUARD CAPITAL MANAGEMENT LLC | $45.0M | 2,004,619 |
| FMR LLC | $44.1M | 1,963,471 |
| STATE STREET CORP | $41.8M | 1,858,051 |
| Ophir Asset Management Pty Ltd | $40.4M | 1,800,008 |
| PERCEPTIVE ADVISORS LLC | $39.0M | 1,737,290 |
| Conestoga Capital Advisors, LLC | $36.5M | 1,623,700 |
Companies Similar to AORT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
SI-BONE, Inc.
iRhythm Holdings, Inc.
Orthofix Medical Inc.
Axogen, Inc.
Evolus, Inc.
SUPERNUS PHARMACEUTICALS, INC.
Xeris Biopharma Holdings, Inc.
CASTLE BIOSCIENCES INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AORT on your watchlist
Track score changes the day ARTIVION, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AORT a good stock to buy?
13F Pro's AI-powered analysis of ARTIVION, INC. (AORT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AORT are available on the AORT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AORT is classified as a small company.
Which hedge funds own AORT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AORT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARTIVION, INC.'s investment landscape.